New Intervention Priority Score in Elsevier's MTM 360 to Enhance Medicare Medication Therapy Management Efforts

By Elsevier, PRNE
Monday, March 29, 2010

ORLANDO, Florida, March 30, 2010 - Elsevier Clinical Decision Support, a leading provider of
medical information and solutions, announced today that it has developed a
quantitative ranking system that enables health plans to better control their
medication therapy management (MTM) programs for Medicare Part D members.

The Intervention Priority Score (IPS) is a new feature of
Elsevier's MTM 360, which is powered by the award-winning, highly accurate
modeling technology of MEDai, an Elsevier company. Elsevier and MEDai
developed the IPS specifically for health plans seeking to improve their
management of MTM programs for their Medicare Part D business.

The new IPS is embedded in MTM 360 and will enable Medicare
Part D sponsors to select members based on a priority ranking of intervention
need. MTM 360 also addresses the CMS requirement to assign priority to health
plan members who have requested a Comprehensive Medication Review, so those
members are moved to the top of the list.

"Medication Therapy Management is an effective component in
the management of multiple chronic conditions," said Swati Abbott, President
and CEO of MEDai. "The development of our Intervention Priority Score allows
health plans to intervene with patients based on a priority ranking that is
determined by applying our modeling technology to patient-specific
information like pharmacy and demographic data. By leveraging the IPS score,
sponsors will be able to target the right members for inclusion in their MTM
program and proactively intervene on those cases with the highest risk and
greatest chance of having an adverse outcome."

MTM 360 was designed to facilitate the collection,
documentation, analysis and reporting of data required as part of CMS's MTM
program protocols. The solution allows clients to not only select eligible
beneficiaries for MTM using CMS rules but also to create specific criteria
that align with other initiatives their organizations are currently involved
in. MTM 360 allows users to identify, stratify and monitor patient
populations to ensure effective and efficient resource allocation. The
program also supplies customizable documentation, communication, and
reporting to streamline the MTM delivery process.

Elsevier's MTM 360 leverages MEDai's modeling technology which
is recognized globally as being the most accurate. Its technology has
consistently yielded the highest accuracy available as evidenced by their
performance in The Association for Computing Machinery's Knowledge Discovery
and Data Mining (ACM KDD) competition, as well as in the German
Classification Society competition, also known as the GFKL, and additionally
in a study conducted by Society of Actuaries.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical
and medical information products and services. The company works in
partnership with the global science and health communities to publish more
than 2,000 journals, including The Lancet (www.thelancet.com) and Cell
(www.cell.com), and close to 20,000 book titles, including major
reference works from Mosby and Saunders. Elsevier's online solutions include
ScienceDirect (www.sciencedirect.com), Scopus (www.scopus.com),
Reaxys (www.reaxys.com), MD Consult (www.mdconsult.com) and
Nursing Consult (www.nursingconsult.com), which enhance the
productivity of science and health professionals, and the SciVal suite
(www.scival.com) and MEDai's Pinpoint Review (www.medai.com),
which help research and health care institutions deliver better outcomes more
cost-effectively.

A global business headquartered in Amsterdam, Elsevier
(www.elsevier.com) employs 7,000 people worldwide. The company is part
of Reed Elsevier Group PLC (www.reedelsevier.com), a world-leading
publisher and information provider, which is jointly owned by Reed Elsevier
PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam),
REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

About MEDai

MEDai, Inc. is a subsidiary of Elsevier that offers award-winning
solutions for the improvement of healthcare delivery. Utilizing cutting-edge
technology, payors and care management organizations are able to predict
patients at risk, identify cost drivers for their high-risk population,
forecast future health plan costs, evaluate patient patterns over time and
improve outcomes. For more information on MEDai, visit www.medai.com.

    Tom Reller
    Vice President, Global Corporate Relations
    +1-215-239-3508
    T.Reller@Elsevier.com

Tom Reller, Vice President, Global Corporate Relations, +1-215-239-3508, T.Reller at Elsevier.com

YOUR VIEW POINT
NAME : (REQUIRED)
MAIL : (REQUIRED)
will not be displayed
WEBSITE : (OPTIONAL)
YOUR
COMMENT :